Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer

Case Reports in Oncology

Volumn 4, Issue 1, 2011, Pages 16-18

  Zardavas, Dimitrios ^a   Meisel, Alexander ^a   Samaras, Panagiotis ^a   Knuth, Alexander ^a   Renner, Christoph ^a   Pestalozzi, Bernhard C ^a   Stenner Liewen, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chromophobe renal cell cancer; Liver metastases; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CASE REPORT; CHROMOPHOBE RENAL CELL CARCINOMA; DRUG DOSE REDUCTION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATURIA; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MESENTERY LYMPH NODE; PALMAR TOXICITY; PLANTAR TOXICITY; PRIORITY JOURNAL; TOXICITY; UNSPECIFIED SIDE EFFECT;

EID: 79957607938     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000323804     Document Type: Article

References (3)

1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
2. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
3. START 'Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy'. ClinicalTrials.gov Identifier: NCT01217931.